BioSpace News Archive

SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”) today announced it has been granted final approval from the Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, required to commence the Company’s Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome (“TS”).

Horizon Therapeutics plc announced that it has been named one of Fortune’s 100 Best Companies to Work For® for the third consecutive year.

LIXTE Biotechnology Holdings, Inc. announced that Sarah Cannon Research Institute at Tennessee Oncology in Nashville, Tennessee, is joining an ongoing Phase 1b clinical trial initiated at City of Hope, one of the largest cancer research and treatment organizations in the United States, to assess the combination of LIXTE’s first-in-class protein phosphatase 2A inhibitor LB-100 with a standard regimen for previously untreated, extensive stage disease small cell lung cancer.

AiCuris Anti-infective Cures AG, a leading clinical stage pharmaceutical company in the development of novel, resistance-breaking anti-infective agents for the treatment of severe and potentially life-threatening infectious diseases, announced the appointment of Larry Edwards as Chief Executive Officer, effective April 1, 2023.

Crown Bioscience, a global contract research organization and JSR Life Sciences company, announced that it has completed its acquisition of the IndivuServ business unit of Indivumed GmbH on March 31, 2023.

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced central Institutional Review Board (“IRB”) approval for the protocol of its Phase 2 study evaluating Ampligen® as a therapeutic for patients with post-COVID conditions (“AMP-518”).

Stratasys Ltd. and CollPlant Biotechnologies announced a joint development and commercialization agreement to collaborate on the development of a solution to bio-fabricate human tissues and organs using Stratasys’ P3 technology-based bioprinter and CollPlant’s rh-Collagen-based bioinks.

BioPhotas, Inc., the manufacturer of the award-winning Celluma SERIES of light therapy devices, announced today that the Company received certification to European Council Medical Device Regulation 2017/745 for low level light therapy devices.

Royal Philips (NYSE: PHG, AEX: PHIA) a global leader in health technology, and Northwell Health, the largest healthcare provider in the state of New York, USA, announced today they have entered into a seven-year agreement to help the health system standardize patient monitoring, enhance patient care and improve patient outcomes while driving interoperability and data innovation.

Centricity Vision Inc. announced that a new study published in the Journal of Cataract & Refractive Surgery demonstrated the superiority of its Precision Pulse Capsulotomy technology over Continuous Curvilinear Capsulorhexis for capsulotomy creation in white cataracts.